← All trials
NCT02607449
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2013
- Primary completion
- Dec 1, 2018
- Completion date
- Dec 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 480
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Scientific Center for Anti-infectious Drugs, KazakhstanLead sponsor
- JSC Scientific Center for Anti-infectious DrugsStudy director
- Almaty City Tuberculosis Dispensary, Almaty, KazakhstanCollaborator
- Regional Anti-TB Dispensary of Karagandy Oblast, KazakhstanCollaborator
- Karaganda State Medical UniversityCollaborator
- Government of KyrgyzstanCollaborator
- Government of KazakhstanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.